The three isoforms of nitric oxide synthase (NOS), spatially confined in specific intracellular compartments in cardiac cells, have distinct roles in the regulation of contractility in pathophysiological situations. Recently, evidence has emerged that implicates NOS in modulating myocardial remodelling during cardiac stress, including after ischaemic insults. As long as they remain in a coupled state the NOS mostly attenuate hypertrophic remodelling through both cGMP-dependent and independent mechanisms. We review the evidence provided from the phenotype of genetic mouse models as well as from in vitro cell experiments dissecting the signalling effectors involved in the NOS-mediated regulation that justify new therapeutic interventions on the NOS-cGMP axis to attenuate the development of heart failure. 
Recap on NOS distribution and function in cardiovascular tissues
Nitric oxide (NO) is a key universal signalling molecule in the cardiovascular system, acting on both acute and more chronic pathways. Nitric oxide is produced from L-arginine by three NO synthases coded by their respective gene, namely NOS1 for neuronal NOS (nNOS), NOS2 for inducible NOS (iNOS), and NOS3 for endothelial NOS (eNOS), expressed in various cardiovascular cell types. 1 Nitric oxide may therefore influence cardiac function through both paracrine and autocrine signalling. In addition, differential subcellular localization of NOS isoforms supports distinct effects on excitationcontraction (E-C) coupling in cardiomyocytes. For instance, nNOS is co-immunoprecipitated with the cardiac ryanodine receptor 2 in sarcoplasmic reticulum (SR) membranes of normal rabbit and human hearts, 2 suggesting a modulation by nNOS-derived NO of SR calcium release. Previous evidence also suggested the presence of NOS in mitochondria. 3 In cardiomyocytes, a subset of eNOS is enriched in plasmalemmal and T-tubular caveolae, where it is associated with caveolin-3, the myocyte-specific structural protein of caveolae, 1 pointing to a role in modulation of membrane-initiated signalling. In addition, such subcellular localization may be dynamic and depends on pathophysiological conditions; accordingly, nNOS can be redistributed from SR membranes to the sarcolemma of cardiomyocytes with the development of heart failure (HF).
superoxide-producing enzyme, and a displaced equilibrium between these two functional states ('uncoupling' of the NOS) promotes the reaction of superoxide with NO to form peroxynitrite (ONOO 2 ), further increasing oxidation of BH 4 , NOS uncoupling, and oxidative/ nitrosative stress; and (v) chaperone proteins, such as heat shock protein 90, that promotes a sustained activation of the enzyme. 1 In contrast, iNOS produces larger amounts of NO and is mainly modulated by transcriptional regulation; its expression can be induced in a wide range of cell types upon pro-inflammatory stimulation. Besides classically promoting vasodilatation and angiogenesis, and opposing platelet adhesion, vascular smooth muscle cell proliferation, and migration, NO has direct and indirect pleiotropic influences on cardiac function, e.g. optimization of E-C coupling or modulation of mitochondrial respiration. More recently, the ability of NOS to modulate redox signalling by balancing the production and reactivity of reactive oxygen species has come into focus. 1,5 -7 Among downstream effectors, NO activates soluble guanylyl cyclase (sCG), leading to the production of cGMP and subsequent activation of cGMP-dependent protein kinase G type 1 (PKG1). PKG1 exerts negative inotropic effects by diminishing L-type Ca 2+ channel currents and through desensitization of cardiac myofilaments to Ca 2+ following troponin I phosphorylation (recently reviewed in reference 8 ). Specific pools of cGMP also regulate the activity of isoforms of the phosphodiesterases (PDE) family that hydrolyse cyclic nucleotides, including cAMP and cGMP itself. Phosphodiesterases probably play an important role in compartmentation of cyclic nucleotides pools. Nitric oxide also exerts biological effects through cGMP-independent mechanisms, including S-nitrosylation of key target proteins, as developed below (section 3.2; Figures 1 and 2 ).
Which NOS isoform in post-ischaemic remodelling? Evidence from in vivo transgenic models
Following ischaemia, the myocardium undergoes repair processes to heal the ischaemic zone and remodels the remaining tissue in order to cope with the haemodynamic stress resulting from the loss of functional muscle. 9 We will now review the evidence implicating NOS and NO in myocardial remodelling, as deduced from the phenotype of mouse models with genetically engineered NOS submitted to various cardiac stresses [e.g. by transaortic constriction, myocardial infarction (MI), followed or not by reperfusion (ischaemia/reperfusion; I/R) in vivo or ex vivo; see also Table 1 ].
Is nNOS protective against ischaemic injury and adverse remodelling?
The course and degree of remodelling is likely to be influenced by the regulation of E-C coupling and its modulation by the NOS in the remaining, viable myocardium. The way in which nNOS regulates E-C coupling in the healthy heart is complex, as suggested by recent (and sometimes contradictory) data using genetic models. One group found that deletion of the NOS1 gene in mice enhanced contractility, 10, 11 with increased Ca 2+ transients and cell shortening at baseline, whereas this was not observed by others. 12 During b-adrenergic stimulation, however, the former group found that myocytes from NOS1 2/2 mice exhibited an increased contractile response, 10 whereas another group observed depressed contractility. 13 Nevertheless, a common feature of all NOS1 As expected, despite the large number of studies performed during the last decade, the exact role played by nNOS in the response to cardiac stress and subsequent remodelling is still being debated. An increased expression and activity of nNOS has been reported after MI-induced HF in rats, coupled with the translocation of this enzyme to the sarcolemma through interactions with caveolin-3. 4 Here pharmacological inhibition of nNOS (with N5(1-imino-3-butenyl)-L-ornithine; 0.1 mM) improved cardiac contractility in failing hearts. Increased expression and activity were also observed in endstage congestive HF in patients with idiopathic dilated cardiomyopathy, whereas eNOS expression was lower than in control patients. 18 This raises the question of whether this nNOS up-regulation is adaptive or deleterious.
Early work had shown that systemic deletion of NOS1 in mice led to spontaneous concentric left ventricle (LV) remodelling, 13 and this was exacerbated following MI. 19, 20 Post-MI, NOS1 2/2 mice showed a faster and more severe LV dilatation compared with their wild-type controls. They responsed to dobutamine with a dramatic fall in LV contractility. 19 Another group showed greater mortality, worse left ventricular fractional shortening, dilatation with a higher LV diastolic diameter, and increased superoxide production after MI in NOS1 2/2 mice. 20 Despite the caveat on the interpretation of the phenotype of systemic knockout animals, these data would support a protective role for cardiac nNOS activity after MI, although it potentially contributes to LV dysfunction through b-adrenergic hypo-responsiveness. More recent data using tissue-specific overexpression models provided further evidence that nNOS can limit functional alterations Nitric oxide synthase attenuates cardiac remodelling subsequent to pressure-overload or post-ischaemic damage. In a transaortic constriction (TAC)-induced pressure-overload model, mice with cardiomyocyte-restricted nNOS overexpression showed concentric hypertrophy with preserved LV fractional shortening, whereas control mice displayed eccentric remodelling and loss of function. As mentioned above (NOS1 tg used by Loyer et al.), 16 this was associated with greater L-type Ca 2+ channel current, Ca 2+ transients and sarcoplasmic reticulum Ca 2+ load in transgenic mice compared with wild-type. This suggests that nNOS may limit the transition to adverse remodelling and HF through preservation of calcium cycling. 16 Some of the protective effects of nNOS could derive from its capacity to counteract the nitroso-redox imbalance that occurs after ischaemia by inhibiting xanthine oxidoreductase (XOR) and mitochondrial reactive oxygen species production. 6 Indeed, cardiac overexpression of nNOS confers protection from I/R injury, in part through inhibition of XOR activity. In these conditions, nNOS was also shown to be translocated to mitochondria via a heat shock protein 90-dependent mechanism. In addition to XOR inhibition, overexpression of nNOS was associated with increased mitochondrial nitrite levels, dithiothreitol-sensitive inhibition of cytochrome c oxidase activity, and lowered ATP consumption. 21 Whether such regulation observed in an overexpression system fully applies to nNOS at endogenous expression levels remains an open question. Nevertheless, the conjunction of nNOS effects to inhibit XOR and mitochondrial ROS production, as well as perhaps L-type Ca 2+ channel current , each supported by the enzyme's subcellular localization in specific settings (I/R or HF) was proposed to contribute to protective effects of the enzyme against post-stress remodelling.
iNOS
At first glance, the numerous studies on stress-induced cardiac remodelling using NOS2 transgenic animals (summarized in the Table 1 ) would not allow univocal conclusions to be drawn on the role of this isoform, but some apparent contradictions may be explained by model-specific features. In one study, cardiac-specific overexpression of iNOS in mice was reported to induce all the features of severe adverse remodelling with conduction defects, and Figure 1 Cyclic GMP-mediated mechanisms for nitric oxide synthase (NOS) regulation of excitation-contraction coupling and hypertrophy in cardiac myocytes. Endothelial NOS (coded by NOS3) localized to the sarcolemma modulates the function of several effectors of excitation-contraction coupling and hypertrophy through activation of the soluble isoform of guanylyl cyclase (sGC) and cGMP-dependent protein kinase (PKG). The latter modulates the excitation-contraction coupling through changes in phosphorylation of the L-type calcium channel (LTCC), myofilament-associated troponin I (Tpn i) and perhaps, phospholamban (PLB) and the ryanodine receptor. Endothelial NOS also associates with the a1G subunit of the T-type calcium channel (TTCC) in a subset of rafts/caveolae, where it is probably activated by calcium entry through this channel; similar downstream cGMP/PKG activation then attenuates pro-hypertrophic pathways, such as calcineurin (CN)/nuclear factor of activated T cells (NFAT); in addition, PKG was shown to inhibit hypertrophy through regulator of G-protein signalling-2 modulation of Gaq signalling, inhibition of transient receptor potential cation channel, subfamily C, member 6 (TRPC6) and the Na + -H + exchanger, NHE. Sildenafil-mediated inhibition of phosphodiesterase (PDE)-5 amplifies specific pools of cGMP, thereby potentiating some PKG downstream effects, e.g. on troponin I; similar pools may be activated by b 3 -adrenoceptor (b3-AR) stimulation of endothelial NOS to modulate hypertrophy (see main text for details and references). Cyclic GMP may also target cAMP catabolism through other isoforms of phosphodiesterases (e.g. PDE-2 and PDE-3) and thereby modulate the contractile response to catecholamines (not shown). Abbreviations: BH 4 , tetrahydrobiopterin; Cav-3, caveolin-3; SR, sarcoplasmic reticulum.
increased mortality, associated with myocardial peroxynitrite production. 22 In contrast, another iNOS-overexpressing mouse strain exhibited no cardiac dysfunction, and this apparent protection was attributed to buffering of excessive NO by myoglobin. 23, 24 As the milder phenotype cannot be attributed to lower NOS activity in the latter study, the divergence could be related to differences in the genetic construction of the two models (cardiac-specific nonconditional 23 vs. tetracycline-inducible transactivator, co-expressing
). In wild-type mice, iNOS expression and activity were shown to increase following myocardial infarction in the infarcted area 25 (approximately four-to five-fold increase of S-methylisothiourea sulfate-inhibitable activity, peaking at 72 -96 h and back to normal at day 14 post-infarction 26 ), but not in the non-infarcted region. However, 5 months after MI, iNOS was no longer detected in the infarcted region but was expressed in the myocytes of remote regions of the myocardium. 27 Long-term administration of selective iNOS inhibitors to rats 28 or NOS2 gene deletion in mice 25, 27 also improved cardiac function after MI, with significant reduction in mortality, suggesting that induction of iNOS post-MI exerts a deleterious influence on cardiac remodelling, although this was not observed in another study. 29 The protection conferred by iNOS deletion appeared at late stages of remodelling (4 months) rather than determining infarct size or early LV remodelling during the first month after MI. 27 In pressure-overload models, deletion of NOS2 did not prevent adverse remodelling, 30 whereas it delayed the establishment of cardiac dysfunction on the long term in another study. 31 Therefore, some of variance in the observed phenotypes may be explained by the timing of the analysis or by different experimental conditions (e.g. extent of the inflammatory reaction). Indeed, expression and activity of iNOS increases not only in cardiac myocytes in HF models (approximately two-fold increase) 32 but also in other infiltrating inflammatory cells, as observed in transgenic mice with cardiac-specific overexpression of tumour necrosis factor-a. 33 Pharmacological inhibition of iNOS using ONO-1714 had no effect on basal contractility but improved b-adrenergic inotropic responsiveness in these mice. 33 Interestingly, other reports consistently associate the deletion 25 or the inhibition of iNOS with enhanced inotropic response to b-adrenergic stimulation in human 34 or rat 32 failing hearts, as initially demonstrated in isolated rat cardiomyocytes. 35 Thus, iNOS may have a causal role in the hypo-responsiveness to b-adrenergic receptor stimulation that, in turn, may participate in the development of LV dysfunction.
Figure 2
Cyclic GMP-independent mechanisms for NOS regulation of oxidant stress and excitation-contraction coupling. Spatially confined NOS may modulate the cardiac myocyte response to mechanical and ischaemic stress via S-nitrosylation (SNO) of several protein effectors of excitationcontraction coupling. In addition to direct modulation of the function of these effectors, one hypothesis proposes that S-nitrosylation is balanced with oxidative stress and may shield proteins against irreversible oxidative damage. Neuronal NOS (coded by NOS1) was also shown to protect from oxidative damage through inhibition of xanthine oxidoreductase (XOR); similar antioxidant mechanisms may be operative after translocation of neuronal NOS to mitochondria. In the setting of ischaemia/reperfusion (I/R), inducible NOS (coded by NOS2) may also exert cardioprotective effects through protein kinase G (PKG) targeting of the mitochondrial K ATP channel (not shown). In other settings, however, inducible NOS exerts a negative influence on b-adrenergic inotropism, although the mechanisms remain unclear (see main text for details and references). Abbreviations: BH 4 , tetrahydrobiopterin; HF, heart failure; SR, sarcoplasmic reticulum. The production of NO in all these conditions probably involves multiple cell types expressing iNOS within the myocardium, 33 as well as more than one NOS isoform. The cell-and isoform-specific contribution can hardly be resolved with systemic administration of NOS inhibitors or systemic NOS2 genetic deletion. Isolated, singlemyocyte contractility assays did establish the role of myocyterestricted iNOS, as mentioned above, 35 but cell-specific genetic deletion would be needed to extend this role in vivo. Indirect evidence for a predominant role of myocyte iNOS was provided by a study using mice with cardiac-specific overexpression of calcineurin (CN/Tg mice) that also overexpress iNOS, produce tumour necrosis factor-a, and develop LV dysfunction. These mice were crossed into the NOS2 2/2 background, and the resulting phenotype was compared with that of chimeric mice reconstituted with bone marrow from NOS2 2/2 or wild-type mice in order to assess the specific role of iNOS in bone-marrow-derived infiltrating cells; this study pointed to iNOS in myocytes as the main culprit for the dysfunction. 36 Importantly, although the evidence points towards a deleterious effect of iNOS in post-ischaemic remodelling, this does not preclude short-term cardioprotective effects in the setting of I/R (for review, see reference 37 ) In a rat model of late ischaemic preconditioning (also called the second window of preconditioning), for instance, inhibition of iNOS at the time of the preconditioning stimulus did not abolish the delayed protection, but it did so if administered immediately before the ischaemic insult (index ischaemia), suggesting that iNOS may not be involved in the trigger stimulus, but is part of the delayed protection. 38 In fact, activation of cardiac NOS during ischaemic preconditioning may be biphasic, with eNOS activity peaking during the preconditioning stimulus and iNOS activity predominating 24 h later. 37 The mechanism of iNOS-mediated protection may involve a reduction of oxidant radicals that prevents mitochondrial permeability transition, as observed in cardiac myocyte-specific iNOS overexpressors submitted to I/R. 39 Therefore, both the intensity and the time window of iNOS overexpression may dictate its differential effect, either protective in the context of preconditioning or deleterious in the presence of sustained inflammatory stimuli, such as in late-stage cardiomyopathy.
eNOS
Endothelial NOS expressed in cardiac myocytes also regulates E-C coupling in physiological conditions. When overexpressed in cardiac myocytes, it attenuates the b 1 -/b 2 -adrenergic increase in inotropy and chronotropy and reinforces the post-synaptic vagal control of cardiac contraction. 40 In addition, eNOS contributes to the fine tuning of contractility by mediating the slow increase in cardiac force in response to stretch (i.e. the Anrep effect).
1,41
As with nNOS, mice with systemic deletion of the NOS3 gene developed hypertrophy with ageing, partly secondary to hypertension. 13 They also developed more LV hypertrophy, fibrosis, and dysfunction following pressure overload in three studies, 42 -44 one of which included a group of NOS3 2/2 mice treated with the antihypertensive drug hydralazine in order to reduce the confounding effects of hypertension. 43 Moreover, the induction of MI in systemic NOS3 2/2 mice induced worse systolic and diastolic function, decreased capillary density, and mortality at 4 weeks. 45 Although these studies highlight a protective role for eNOS from remodelling, the use of systemic knockout mice does not resolve the question of whether the 'protective' eNOS pool localizes in endothelial cells, cardiac myocytes, or any additional cell type(s). Despite the lack of cell-specific genetic deletion experiments to settle this issue (which remains for all cardiac NOS), data obtained from 'tissuespecific' transgenic animals at least provided useful hints. Consistent with abundant localization of eNOS in vascular endothelium, Jones et al. reported that MI-induced congestive HF was attenuated in mice with endothelium-restricted eNOS overexpression. 46 Several studies provided evidence that cardiomyocyte-restricted overexpression of eNOS under the control of the a-myosin heavy chain promoter (aMHC-eNOStg) could also protect against adverse remodelling after TAC 47 or MI, 48 although fibrosis was not improved. 48 Of note, a recent study using isolated single myocytes also demonstrated that eNOS is the main source of constitutively produced NO (i.e. in the absence of inflammatory stimuli) in response to angiotensin II, a typical mediator of remodelling. 49 This, together with the fact that eNOS co-localizes with specific downstream effectors confined to specific subcellular domains in cardiac myocytes (see following section 3.1), highlights eNOS-derived NO both as a critical regulator of remodelling and as an attractive therapeutic target to prevent and/or treat post-ischaemic remodelling and HF. However, the efficiency of eNOS (as all NOS) signalling depends on the balance between its 'coupled' (in dimeric form, producing NO) vs. 'uncoupled' (monomeric, producing superoxide anion) status (see section 1, above), with the latter producing deleterious effects during conditions of heavy, long-term haemodynamic overload. 50 Interestingly, BH 4 supplementation restored the protective effect of NOS in the context of severe cardiac remodelling, and this mechanism was shown to act specifically on cardiac eNOS but not endothelium-derived eNOS from heart blood vessels. 50 The effect of BH 4 supplementation may not be restricted to eNOS, because iNOS-derived superoxide generation was reduced (and NO bioavailability increased) by BH 4 in a model of I/R injury in perfused hearts from diabetic rats. 51 Thus, promoting the 'coupled' status of NOS activity in cardiac myocytes by BH 4 supplementation offers an interesting therapeutic approach (see section 4.2 below) and justifies further study of the mechanism for both eNOS activation and downstream regulation of pathological remodelling.
NOS-mediated pathways influencing remodelling 3.1 The NO -cGMP -PKG axis
Substantial evidence points to the soluble guanylyl cyclase (sGC) -cGMP-PKG pathway, a classic target of NO, as a regulator of stress-induced cardiac remodelling downstream of NOS. Although most of the in vivo data used models of pressure overload subsequent to thoracic aortic banding, similar mechanisms are probably also involved in post-ischaemic remodelling, during haemodynamic stress resulting from the loss of functional myocardium. 52 Initial in vitro data showed that the NO donor, S-nitroso-N-acetyl-D,L-penicillamine, the cGMP analogue 8-Bromoguanosine-3 ′ ,5 ′ -cyclic monophosphate (8-Br-cGMP), 53 and adenoviral overexpression of PKG1 54 exert antihypertrophic effects on catecholamine-stimulated cardiomyocytes. S-nitroso-N-acetyl-D,L-penicillamine and 8-Br-cGMP also prevented the proliferation of cardiac fibroblasts. 53 These effects could be at least partly mediated by inhibition of the classic Ca 2+ -sensitive prohypertrophic calcineurin/nuclear factor of activated T cells (NFAT) signalling pathway (recently reviewed in reference 8 ). Consonant with these in vitro data, the preferential PDE5 inhibitor, sildenafil, Nitric oxide synthase attenuates cardiac remodelling not only prevented but also reversed TAC-induced adverse remodelling and the activation of pro-hypertrophic pathways in mice. However, as cGMP is also produced by the particulate GC (GC-A) upon binding of natriuretic peptides, NOS activity may not be the only source of cGMP mediating protection. Cardiac-restricted deletion of GC-A showed that natriuretic peptide mediates an antihypertrophic action in the heart, independent from its role in regulating blood pressure. Thus, sGC-dependent and GC-A-dependent pools of cGMP may converge on some common pathways regulating hypertrophy, including Calcineurin (Cn)-NFAT. Nevertheless, the sildenafil-sensitive pool of cGMP that regulates cardiac inotropy seems to be orchestrated by eNOS and not by natriuretic peptides. 55 Taken together, these data suggest a mechanism whereby eNOSderived NO would activate sGC and generate a subcellularly confined pool of cGMP, leading to activation of a subset of PKG1 and upstream attenuation of signalling pathways involved in hypertrophy.
There may be several relevant targets of PKG1 in the context of stress-induced remodelling. 8 waves governing contractility. In this context, the co-localization of eNOS and (a subset of) sGC and PKG in the vicinity of some of these Ca 2+ handling effectors probably has functional relevance.
Indeed, in vitro data showed that the phosphorylation of TRPC6 by PKG (stimulated with 8-Br-cGMP or sildenafil, which specifically affects the eNOS-dependent cGMP pool) 55 can prevent TRPC6-mediated NFAT activation. 58 Moreover, a direct association was shown between eNOS and the a1G T-type Ca 2+ channel that conferred protection from adverse remodelling in vivo. 59 The channel subunit co-immunoprecipitated with eNOS, and inhibition or deletion of eNOS abrogated the protective effect conferred by inducible, cardiac-specific overexpression of the a1G protein. Protein kinase G activity was also increased in heart extracts from these transgenic mice after pressure overload. The fact that both eNOS (also a Ca 2+ -sensitive enzyme) and the a1G trophy. Among these, the regulator of G-protein signalling-2, which is known to attenuate the transduction of G q signalling, was shown to attenuate pressure overload-induced hypertrophy and to mediate the anti-hypertrophic effects of sildenafil in vivo. In addition to regulating hypertrophy of cardiomyocytes, the cGMP-PKG axis may influence other important aspects of remodelling, such as angiogenesis and fibrosis, thereby extending the potential benefits associated with activation/restoration of NOS activity. Recently, the pivotal role of PKG1 in attenuating pressure overload (or neurohormone)-induced hypertrophy was questioned, based on the phenotype of mice with genetic ablation of PKG1. 60 As the systemic deletion is lethal, a first model used 'rescue' PKG1a expression under a smooth muscle cell promoter on a PKG1 2/2 background, leaving other cells, including cardiomyocytes, depleted of the enzyme. These mice did not exhibit enhanced hypertrophy in response to catecholamines or TAC; however, aside from potential problems with the model itself, the stress imposed on the mice in this study may have been too mild to fully activate PKG and/or its known targets mediating the hypertrophic response, e.g. NFAT and Ca 2+ -calmodulin-dependent kinase. 60 Indeed, in other mouse models with either expression of a mutant form of PKG1a (unable to bind effectors) 61 or with cardiomyocyte-restricted deletion of PKG1a, 8 TAC did produce a worse remodelling, with deterioration of cardiac function. Likewise, although sildenafil may target PDE1 in addition to PDE5 in some species (e.g. humans), its cGMP-potentiating and protective effect was shown to depend on PKG1a expression, at least in mice. 61 Finally, the possibility that the cGMP-stimulated PDE2 mediates the effects of sildenafil upon catecholamine (i.e. G s -coupled isoprenaline) stimulation seems unlikely, given that PDE2 inhibition had no influence on the sildenafil-induced negative inotropic effect upon isoprenaline stimulation. 62 Again, this points to specific signalling modulation by spatially confined pools of cGMP.
cGMP-'independent' protective effects of NO
In addition to the cGMP axis, NO modulates many effector proteins through nitrosylation, i.e. the post-translational covalent modification of a protein cysteine thiol by a NO group to generate S-nitrosothiols (for a review see reference 63 ). S-nitrosylation was shown to regulate numerous functions in cardiovascular tissues, including vascular tone, angiogenesis, inflammation, apoptosis, E -C coupling, and G-protein-coupled receptor signalling. In the context of myocardial injury or failure, the production of reactive oxygen species, e.g. superoxide anions from mitochondria, NADPH and xanthine oxidase activities may alter NO biological signalling by directly reacting with NO (to produce peroxinitrite, ONOO 2 ), competing with NO for irreversible, covalent binding with cysteine thiols, and by directly limiting NO synthesis by NOS oxidation and uncoupling. 6 Maladaptive remodelling may therefore be the consequence of the decreased bioavailability/bioactivity of NO produced by NOS in specific compartments where it normally regulates cardiac and coronary functions via protein S-nitrosylation. Such nitroso-redox imbalance has been observed in hypertensive rats with HF, where global nitrosylation of myocardial proteins is reduced and can be restored by treatment with oxypurinol, a xanthine oxidase inhibitor. 64 In this context, the protection conferred by nNOS against post-MI remodelling (see previous section 2.1) could be due to its inhibition of XOR, 65 as reproduced by cardiac overexpression of nNOS in I/R injury. 21 Importantly, S-nitrosylation is a reversible and dynamic process. S-nitrosogluthathione reductase (GSNOR) is a key enzyme for de-nitrosylation. 66 An important insight on the extent of cardioprotection conferred by S-nitrosylation was provided by a study of GSNOR knockout mice submitted to MI. These mice with enhanced S-nitrosylated proteins show reduced myocardial infarct size, preserved ventricular systolic and diastolic function, and blunted eccentric remodelling 12 weeks after MI. Constitutive S-nitrosylation of hypoxia-inducible factor was proposed as a central (albeit not exclusive) mechanism for this protection. 67 Using a new resin-assisted capture technique, Kohr et al. 68 recently studied the dynamics of nitrosylated and oxydized thiol residues in proteins from heart tissue following I/R preceded or not by ischaemic preconditioning. They showed that the amount of nitrosylated proteins was increased by preconditioning, and that the degree of oxidation of this particular protein pool was lower than in non-nitrosylated proteins. This led them to propose that initial, transient nitrosylation could act as a 'shield', preventing protein thiols from subsequent oxidation during the reperfusion phase. Several protein targets have been identified for nitrosylation by endogenous NOS that could account for their protective effects. A recent study 69 70 -72 and is enhanced after I/R via eNOS and nNOS activities. 71, 72 This could be facilitated by co-localization of the channel with both enzymes into caveolae. Likewise, nitrosylation of the cardiac ryanodine receptor 2 was shown to increase its open probability. 2 Limited, regulated nitrosylation of ryanodine receptor 2 by eNOS may underlie the slow increase in calcium and contractile force (i.e. the Anrep effect) in isolated mouse and rat cardiomyocytes in response to stretch. 41 ). S-nitrosylation of phospholamban was described in fish hearts, 74 but with no equivalent in mammals so far. Finally, S-nitrosylation also regulates energy metabolism (particularly through mitochondrial targets), 68 although the implications for post-ischaemic remodelling need further study. Spatial confinement of eNOS or nNOS in the normal heart or their translocation in pathophysiological situations probably guarantees both efficient and specific S-nitrosylation of these effectors; co-localization of the NOS with GSNOR would probably add another layer of regulation, but has been little studied so far. Combination of oxidative stress and NO production can also lead to modifications of lipids through formation of biologically active nitro-fatty acids. 75 The relevance of nitro-fatty acids in cardiac pathophysiology was suggested by a recent in vivo study showing that mice having undergone I/R have increased levels of nitro-oleic acid and nitro-linoleic acid compared with control animals. 76 Interestingly, administration of nitro-oleic acid reduced the severity of the reperfusion-induced injury and inflammatory reaction, and slightly improved fractional shortening. Such data add further complexity to the potential biological effects of NO and oxidant radicals but also suggest interesting new therapeutic directions that deserve further investigation.
Translational perspectives of NOS modulation in post-ischaemic remodelling
The above sections highlight the growing weight of evidence in favour of the causality of cardiac NOS in driving adaptive (with fully functional NOS) vs. maladaptive remodelling (with dysfunctional NOS). The following paragraphs examine how this knowledge can be translated into therapeutic approaches by targeting specific cardiac NOS and/ or downstream pathways.
Phosphodiesterase 5A inhibitors and soluble guanylyl cyclase activators
As discussed above (section 3.1), convincing evidence supports the benefit of strategies reinforcing the NO-cGMP-PKG1 axis to limit adverse post-ischaemic cardiac remodelling. Indeed, the abundance of the cGMP-hydrolysing PDE5 protein was increased in hearts from patients with advanced systolic HF due to ischaemic or dilated cardiomyopathy in comparison with heart tissue from control patients, 77 and transgenic mice with cardiac-restricted PDE5 overexpression were predisposed to adverse left ventricular remodelling with reduced contractile reserve after myocardial infarction. This provides a rationale for the therapeutic use of PDE5 inhibitors or sGC activators to preserve the cGMP pool and the associated protective effects. The relevance of PDE5 as the main (or exclusive) cGMP-hydrolysing enzyme in the heart is, however, debatable, because PDE1 may also be involved and is inhibited by sildenafil at high doses. 78 Data comparing cGMP-hydrolysing activities confirmed the importance of PDE5 in normal and failing mouse hearts but less so in failing human myocardium. This stresses the need for a thorough characterization of cGMP-hydrolysing activities in human disease, in order to target the most relevant PDE isoform with specific inhibitors. Nevertheless, sildenafil is currently being tested in a National Institutes of Health sponsored clinical trial of diastolic HF (Evaluating the effectiveness of sildenafil at improving health outcomes and exercise ability in people with diastolic heart failure -The RELAX Study). The direct sGC activator BAY 58-2667 showed protective properties by reducing infarct size in perfused rodent hearts submitted to I/ R, 79 
The b 3 -adrenergic pathway
In the human and mouse ventricle, b 3 -adrenergic receptors (ARs) exert an inotropic influence that is mediated by eNOS activation and functionally antipathetic to that of b 1 -and b 2 -adrenergic stimulation. 86, 87 This suggests the importance of b 3 -ARs for eNOS-mediated blunting of the cardiac effects of neurohormones. Moreover, a similar inhibition of the b 1 -and b 2 -adrenergic inotropic effect by sildenafil in mouse cardiomyocytes was recently shown to be mediated by the b 3 -AR. 62 Therefore, several pieces of evidence converge to the involvement of b 3 -ARs to stimulate, via eNOS, the production of a cGMP pool that is sensitive to sildenafil in the context of cardiac stress, e.g. with neurohormonal stimulation. Additional facts would reinforce the interest in such possibility (for reviews, see references 88, 89 ), as follows: (i) in contrast to b 1 -and b 2 -adrenergic receptors, the expression of b 3 -ARs was shown to increase in patients with ischaemic and dilated cardiomyopathies; 90 (ii) the b 3 -AR lacks consensus phosphorylation sites involved in receptor desensitization; (iii) although acute stimulation of b 3 -ARs attenuates contractile shortening of ventricular muscle in vitro, 86 chronic overexpression of b 3 -ARs in vivo does not result in contractile dysfunction or decreased contractile reserve. 91, 92 Interestingly, mice with systemic deletion of the b 3 -AR develop age-dependent cardiac hypertrophy. Moreover, b 3 -AR knockout mice showed worse remodelling than wild-type mice following TAC, including enhanced fibrosis, cardiomyocyte hypertrophy, and LV dilatation. 93 Reciprocally, data from our group 91 show that transgenic mice with cardiac-restricted b 3 -AR overexpression are protected from cardiac hypertrophy induced by chronic infusion of neurohormones, and that this protection is reversed by NOS inhibition. Further data recently showed that the protection against I/R injury and increased phosphorylation of Ser-1177 of cardiac eNOS conferred by voluntary exercise were lost in b 3 -AR 2/2 mice. 94 Acute administration of the preferential b 3 -AR agonist, BRL37344, was recently reported to decrease contractility slightly (assessed by pressure-volume loop analysis) in nonfailing hearts of normal sheep but, strikingly, it improved LV function in post-ischaemic failing hearts. 95 Mechanistically, this was attributed to b 3 -AR stimulation of Na + -K + -ATPase activity by reducing glutathionylation of the b Na + -K + pump subunit, through a NOSdependent mechanism. Whether this would also prevent adverse myocardial remodelling upon chronic b 3 -AR stimulation still remains to be studied. There is only indirect evidence, so far, that such protective effects may be relevant to human HF. One such piece of evidence is the result from the SENIORS trial, 96 which established the benefit of nebivolol in an elderly population of patients with HF. Nebivolol is endowed with dual b 1 -AR blockade and b 3 -AR agonistic properties, as demonstrated ex vivo in human microcoronary arteries 97 and human non-failing myocardium. 98 Although superiority compared with a 'pure' b 1 -AR blocker was not demonstrated, at least it suggests that the additional b 3 -AR stimulation may not be harmful. A direct comparison of nebivolol with the b 1 -AR antagonist, metoprolol, in post-MI remodelling was recently performed in mice and demonstrated a superior efficacy of nebivolol to preserve LV ejection fraction and survival 4 weeks after MI. 99 Notably, these additional benefits were lost in NOS3 2/2 mice, again pointing to a mechanistic role of eNOS-derived NO.
Conclusion
After the original descriptions of the functional role of the cardiac nitric oxide synthases, 100 -102 the last decade has seen a tremendous amount of information contributed from experimental research confirming their expression, regulation, and signalling to specific pathways regulating myocardial remodelling; this involves both cGMP-dependent and independent effectors, whose role is increasingly being deciphered from the phenotype of genetically modified mouse models. These data, together with analysis at the cardiomyocyte level, emphasize the specialized, non-redundant role of each cardiac NOS, subserved by their spatial confinement and co-localization with specific targets that ensure signalling specificity. Accordingly, pools of cGMP have been identified, with nonoverlapping function in their regulation of E-C coupling or hypertrophy. Such compartmentation is particularly relevant for the regulation, by the cardiac NOS, of the nitroso-redox balance that is key for cellular homeostasis in the face of ischaemic, inflammatory, or other pro-oxidant stresses. Future research will probably expand on the molecular characterization of signalosomes around the NOS, including upstream G-protein-coupled receptors or other receptors and associated regulators/effectors; among these, it will be interesting to dissect the molecular determinants of the subcellular localization of effectors, such as PKG1 in cardiac myocytes, or of GSNOR that may preferentially regulate S-nitrosylation of NOS targets. Likewise, the biochemical machinery known to regulate NOS 'coupled' catalytic activity in vascular tissue has been very little studied in the context of cardiac myocytes so far, but should receive more attention, given the emerging role of the nitric oxide synthases as gatekeepers of reactive oxygen species-mediated myocardial dysfunction and remodelling. Hopefully, this should expand the current list of therapeutic options to prevent/reverse post-ischaemic cardiomyopathies through more efficient harnessing of cardiac NOS signalling.
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